A federal District Court in New York recently ruled, in Association for Molecular Pathology et al. v. U.S. Patent and Trademark Office et al. that isolated human genes are not patentable subject matter. While this case (commonly referred to as the Myriad case) challenges the availability of patents on isolated genes and their fragments, its reasoning, if upheld on appeal, could be extended to invalidate patents on other natural products, such as natural antibiotics, natural proteins, etc.
In the two-minute video below Jorge Goldstein provides a brief update on the scope of the case and its potential impact.
Link to this comment:
All Comments (0)